Leukemia (1998) 12, 1518–1521  1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu Clinical study of 9-cis (LGD1057) in acute promyelocytic leukemia SL Soignet1, F Benedetti1, A Fleischauer1, BA Parker2, JA Truglia2, M Ra Crisp2 and RP Warrell Jr1

1Developmental Chemotherapy and Leukemia Services, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Cornell University Medical College, New York, NY; and 2Ligand Pharmaceuticals Inc. San Diego, CA, USA

The use of all-trans retinoic acid (RA) for remission induction some proliferation-associated proteins.14–17 Whereas all-trans markedly increases survival of patients with acute promyelo- RA binds only RARs, 9-cis RA binds and activates both RARs cytic leukemia (APL) compared to patients treated solely with 18–20 cytotoxic chemotherapy. However, clinical resistance to this and RXRs. Preclinical studies also showed that 9-cis agent develops rapidly, which has been associated with a pro- RA was more potent than all-trans RA in inducing myeloid gressive decline in plasma drug concentrations. Previous stud- differentiation in HL60 cells.21,22 ies suggested that 9-cis RA, a receptor ‘pan agonist’ In a preliminary report, we found that 9-cis RA could did not induce its own catabolism to the same extent as all- induce complete remission in APL, but the drug did not trans RA. Therefore, we conducted a dose-ranging study of this appear capable of reversing clinically acquired retinoid resist- compound in patients with both relapsed and newly diagnosed 23 APL. We treated 18 patients with morphologically diagnosed ance. In this final report, we show non-comparative data APL (13 relapsed, five newly diagnosed). The daily dose of 9- that suggests 9-cis RA can induce remission in both previously cis RA ranged from 30 to 230 mg/m2/day given as a single oral treated and newly diagnosed patients at a level that appears dose. Four of 12 (33%) relapsed patients (three of whom were at least equivalent to that of all-trans RA. previously treated with all-trans RA) and four of five (80%) newly diagnosed patients achieved complete remission. The sole failure in the newly diagnosed group died early from an intracranial hemorrhage. One other patient with t(9;12) translo- Materials and methods cation had substantial hematologic improvement. The drug was generally well tolerated; headache and dry skin were the most common adverse reactions. Three patients were treated with Study design corticosteroids for signs of incipient ‘RA syndrome.’ These pre- liminary data suggest that 9-cis RA is an effective agent for Both newly diagnosed and relapsed patients with APL were remission induction and deserves further investigation in patients with retinoid-sensitive APL. eligible for entry into this dose-ranging study. 9-cis RA Keywords: 9-cis retinoic acid; acute promyelocytic leukemia; differ- (supplied as ALRT1057; LGD1057: Panretin) was supplied in entiation soft gelatin capsules containing either 10 or 25 mg of drug (Ligand Pharmaceuticals, San Diego, CA, USA). The lowest daily dose was 30 mg/m2, which was given as a single daily Introduction oral dose until clinical response, or failure (eg rising blast count in peripheral blood or bone marrow, etc) was determ- Acute promyelocytic leukemia (APL) is characterized by ined. In patients who achieved complete remission (CR), ther- reciprocal translocations between chromosomes 15 and 17 apy was continued for approximately 30 days after the date that fuse genes encoding PML and a nuclear retinoic acid of CR. Dose escalation in the same patient was not performed. receptor (RAR-␣).1,2 The resulting fusion gene, PML/RAR-␣, This study was conducted in parallel with a phase 1 study in 24 encodes a chimeric protein that blocks normal myeloid differ- patients with non-hematological neoplasms, which in part entiation.3 The use of all-trans RA for remission induction of determined the dose that could be concurrently used in APL APL, followed by consolidation with several cycles of cyto- patients. Once a relatively high effective dose for remission 2 toxic chemotherapy, has increased survival almost three-fold induction was identified (230 mg/m ), doses in subsequent compared to patients treated with chemotherapy alone.4–9 A relapsed patients were progressively de-escalated in an effort major limitation of all-trans RA therapy is the development of to establish the lowest effective dose. Newly diagnosed retinoid resistance,5,10 which is manifested clinically by a lim- patients were enrolled at doses that had been determined ited duration of remission in patients treated with all-trans RA effective for remission induction in relapsed patients. alone, who are then clinically unresponsive to further retinoid Newly diagnosed patients who achieved CR received exposure. Patients on continuous all-trans RA therapy manifest additional therapy as consolidation, which generally consisted a progressive decline in plasma drug levels,10,11 and this of three cycles of idarubicin and cytosine arabinoside. The observation has engendered speculation that acquired retinoid first cycle was equivalent to a full-dose induction course (ie 2 resistance was related to autoinduced catabolism of the idarubicin 12 mg/m /day for 3 days, plus cytosine arabinoside 2 drug.10–13 200 mg/m /day for 5 days). The subsequent two courses used 2 In 1990, the family of retinoid ‘X’ receptors (RXRs) was idarubicin 12 mg/m /day for 2 days and cytosine arabinoside 2 described, which were shown to act as cofactors for RARs as 100 mg/m /day for 5 days after recovery from the preceding well as receptors for vitamin D, thyroid hormone and peroxi- cycle. Selected patients also received therapy with a recombi- nant humanized monoclonal antibody directed against CD33 (rHuM195).25 Patients who were treated after relapsing from prior therapy and who achieved CR with 9-cis RA received a Correspondence: RP Warrell Jr, Memorial Sloan-Kettering Cancer variety of post-remission therapies. Center, 1275 York Avenue, New York, NY 10021, USA; Fax: 212 During the study, patients were monitored with periodic 717-321 Presented in part at the International Society of Haematology in Stock- determinations of complete blood counts, serum biochemical holm, Sweden, September 1, 1997 analyses, and bone marrow aspirates and/or biopsies. The Received 17 March 1998; accepted 15 June 1998 clinical protocol was reviewed and approved in advance by 9-cis retinoic acid in acute promyelocytic leukemia SL Soignet et al 1519 this center’s Institutional Review Board. Signed informed con- complete remission with arsenic trioxide. One child (18 sent was obtained from all patients. month old female) with a 9;12 translocation was previously resistant to three cycles of chemotherapy and an abbreviated 17 day course of all-trans RA. Shortly after beginning 9-cis RA Results (140 mg/m2/day), she developed progressive leukocytosis and respiratory distress that ultimately required endotracheal intu- Patient characteristics bation, mechanical ventilation and cessation of therapy. Her clinical condition was consistent with both ‘retinoid acid syn- Between February 1994 and July 1996, 18 patients were drome’ and Pneumocystis pneumonia, and she was treated enrolled. Twelve patients with molecularly confirmed APL with corticosteroids and trimethoprim/sulfamethoxazole. had been previously treated with chemotherapy and 11 of Upon recovery, she had attained marked improvement in both these 12 patients had received prior all-trans RA. One of these her total granulocyte and platelet counts (see Figure 1); how- patients had relapsed from an allogeneic T cell-depleted bone ever, further therapy was declined by her parents and marrow transplant, and one patient had previously received a she expired approximately 2 months later from progressive monoclonal antibody in addition to all-trans RA and cytotoxic leukemia. chemotherapy. Five patients were treated at the time of their initial diagnosis. Relevant characteristics of this patient group are presented in Table 1. The diagnosis of APL was confirmed Adverse effects in 17 of 18 patients by cytogenetics or RT-PCR for PML/RAR- ␣. Despite morphological characteristics that were typical of 9-cis RA was generally well tolerated (Table 3). The most APL, one patient had a variant (9;12) translocation (see common adverse reactions were headache (76%) and dry skin below). (59%). Three patients were treated with high-dose cortico- steroids for signs suggestive of incipient ‘RA syndrome’ (eg weight gain, hectic fever, etc). Four patients experienced bone Clinical efficacy pain that required narcotic analgesics. One patient developed hypercalcemia. Minor adverse effects included liver function Four of the 12 (33%) previously treated confirmed APL abnormalities (ie increases in serum alkaline phosphatase and patients (three of the four CR patients had previously received aspartate aminotransferase activity). all-trans RA) and four of the five (80%) newly diagnosed patients achieved complete remission. The median time to CR was 51 days (range, 23–61 days). Doses that were effective in Discussion inducing complete remission ranged from 50 to 230 mg/m2 (Table 2). Seven of the eight patients who achieved CR were The use of all-trans RA during remission induction has been positive for PML/RAR-␣ by RT-PCR at the time of CR, whereas a major advance in the treatment of APL. Since the introduc- only one was negative. Seven of these patients received con- tion of all-trans RA in the early 1990s, several international solidation with a recombinant humanized anti-CD33 mono- groups have reported a marked increase in both disease-free clonal antibody (rHuM195); the assay converted to negative and overall survival.4–9,26 We recently reported a 5-year in three of the seven patients after antibody therapy alone. update of our experience, which showed approximately 2.5- Three of the newly diagnosed patients who achieved CR fold increase in the proportion of patients alive 5 years from remain alive in first remission for durations ranging from 17+ diagnosis compared with patients who were solely treated to 27+ months. One newly diagnosed patient relapsed after a with chemotherapy.9 However, therapy with all-trans RA has remission duration of 19.3 months. Subsequently, this patient presented several new challenges including development of failed remission induction with all-trans RA but ultimately the ‘RA syndrome’ and the emergence of RA resistance in achieved a second remission with cytotoxic chemotherapy. patients who relapse. Three of the four relapsed patients who achieved CR had Previous studies have shown that continuous therapy with remission durations that have ranged from 14+ to 40+ months; all-trans RA results in a progressive decline in plasma drug one patient relapsed and died 9 months later. One of these levels.10–13 Various mechanisms for this phenomenon have three patients relapsed a second time after a remission dur- been postulated, including induction of cytochrome P450 oxi- ation of 29.6 months and was subsequently reinduced into a dases,12,22 an increase in oxidative cofactors (especially lipid hydroperoxides),17,27 and an increased expression of cytoplas- mic RA-binding proteins.28 Inhibitors of P450 enzymes, such Table 1 Pretreatment characteristics of patients treated with 9-cis as ketoconazole or liarozole, transiently increase plasma lev- retinoic acid els of all-trans RA.12,13 However, these agents have not been No. of patients treated 18 reported as decreasing the incidence of clinical resistance nor Median age, years (range) 41 (1.5–69) overcoming clinically acquired retinoid resistance. Theoreti- Sex (male/female) 9/9 cally, this declining drug level could facilitate the emergence Diagnosis: and eventual overgrowth of relatively resistant leukemic cells. Newly diagnosed APL 5 In a previous study, we23,24 and others23,24 found that 9-cis Relapsed APL 12 RA was associated with a somewhat different pattern of t(9;12) myeloid leukemia 1 Previously treated with all-trans RA 11 adverse reactions than all-trans RA. Mucous membrane Median initial peripheral blood leukocyte 2.5 (0.7–17.7) effects, such as cheilitis, xeroderma or skin peeling, occurred count, cells/mm3 (range) in approximately 90% of patients treated in phase 1 trials of Elevated fibrin degradation products at 7/11 (29–31) all-trans RA.29–31 Conversely, these adverse reactions were baseline (Yes/No) observed in less than half of the patients in our study with 9- cis RA. However, hyperlipidemia (particularly hyper- 9-cis retinoic acid in acute promyelocytic leukemia SL Soignet et al 1520

Figure 1 Response in peripheral blood leukocytes (left axis) and platelets (right axis) in a patient with acute promyelocytic leukemia charac- terized by a t(9;12) translocation during treatment with 9-cis retinoic acid. Despite the atypical translocation, the disease appeared retinoid- responsive, with induction of hyperleukocytosis and recovery from severe thrombocytopenia.

Table 2 Dose escalation schedule and response to 9-cis retinoic acid

Dose (mg/m2/day) No. of patients treated No. of patients achieving CR

Newly diagnosed Previously treated Newly diagnosed Previously treated

3002 00 5004 01 14054 42 23003 01 No. of patients achieving complete remission: 8 Previously treated (n = 12) 4 Newly diagnosed (n = 5) 4 Median number of treatment days to complete remission (range): 51 (23–61)

Table 3 Adverse reactions in patients with APL treated with 9-cis retinoic acid

Dose 30 50 140 230 Total No. patients treated n = 2n= 4n= 9n= 3n= 18 Toxicity grade 1 2 3 4 1 2 3 4 1234 1234 1234

Headache 0 0 0 0 3 1 0 0 3230 2010 8340 Mucocutaneous reactions 1 0 0 0 2 0 0 0 7200 0100 9300 Dyspnea 1 0 0 0 1 0 0 0 2100 0000 4100 Bone pain 0 0 0 0 0 1 0 0 1110 0000 1210 Nausea/vomiting 0 0 0 0 1 0 0 0 5100 1000 7100 Facial flushing 0 0 0 0 0 1 0 0 4000 1000 5100 Fatigue 1 1 0 0 0 0 0 0 2000 1000 4100

triglceridemia) and hypercalcemia was observed in 42 and activation suggested that this ligand might exert unique bio- 44% of patients, respectively, in the initial study of 9-cis RA logical activities. 9-cis RA appears to be at least as effective as from this center.24 Relatively stable plasma levels of 9-cis have all-trans RA for remission induction in patients with retinoid- been maintained with chronic dosing up to 140 mg/m2, but sensitive APL. Although this agent does not appear to over- that at higher doses, plasma AUCs have tended to decrease come clinically acquired retinoid resistance, its more stable over time.24,30 plasma concentrations at lower dose levels, which are clini- The retinoid receptors bind their cognate ligands with vary- cally effective, suggest its possible utility as a maintenance ing affinity. For example, all-trans RA primarily binds RARs therapy in APL. and has very low affinity for RXRs. By contrast, 9-cis RA binds This study confirms that 9-cis RA can induce complete both RARs and RXRs with high affinity, and this pan-receptor remission in patients with retinoid-sensitive APL. Given the 9-cis retinoic acid in acute promyelocytic leukemia SL Soignet et al 1521 exploratory nature of this study, we could not reliably deter- acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993; mine the comparative advantage of 9-cis vs all-trans RA. How- 85: 1921–1926. ever, this new agent is clearly effective for remission induction 13 Miller VA, Rigas JR, Muindi JRF et al. Modulation of all-trans reti- noic acid pharmacokinetics by liarozole. Cancer Chemother Phar- in retinoid naive patients with a molecularly confirmed diag- macol 1994; 34: 522–526. nosis of APL. 14 Carlberg C, Bendik I, Wyss A et al. Two nuclear signaling path- ways for vitamin D. Nature (Lond) 1993; 361: 657–660. 15 Mangelsdorf DJ, Ong ES, Dyck JA et al. Nuclear receptor that Acknowledgements identifies a novel retinoic acid response pathway. Nature (Lond) 1990; 345: 224–229. 16 Yu VC, Delsert C, Anderson B et al. RXRB: a coregulator that This work was supported in part by grants from the American enhances binding of retinoic acid, thyroid hormone, and vitamin Cancer Society (EDT-47), Ligand Pharmaceuticals Inc., and D receptors to their cognate response elements. Cell 1991; 67: The Lymphoma Foundation. Steven Soignet is a Mortimer J 1251–1266. Lacher Fellow. 17 Keller H, Dreyer C, Medin J et al. Fatty acids and control lipid metabolism through activation of peroxisome proliferator- activated receptor- heterodimers. Proc Natl Acad Sci USA 1993; 90: 2160–2164. References 18 Mangelsdorf DJ. receptors. Nutr Rev 1994; 52: S32– S44. 1 de The´ H, Chomienne C, Lanotte M et al. The t(15;17) translo- 19 Heyman R, Mangelsdorf D, Dyck J et al.9-cis retinoic acid is cation of acute promyelocytic leukaemia fuses the retinoic acid a high affinity ligand for the retinoid X receptor. Cell 1992; 68: receptor-␣ gene to a novel transcribed locus. Nature 1990; 347: 397–406. 558–561. 20 Levin A, Strzenbecker L, Kazmer S et al.9-cis retinoic acid stereo- 2 Kakizuka A, Miller WH Jr, Umesono K et al. Chromosomal translo- isomer binds and activates the nuclear receptor RXR-␣. Nature cation t(15;17) in human acute promyelocytic leukemia fuses RAR 1992; 335: 359. alpha with a novel putative transcription factor, PML. Cell 1991; 21 Kizaki M, Yasuo I, Tanosaki R et al. Effects of novel retinoic acid 66: 663–674. compound, 9-cis retinoic acid, on proliferation, differentiation, 3 Early E, Moore MAS, Kakizuka A et al. Transgenic expression of and expression of -␣ and retinoid X receptor PML/RAR␣ impairs myelopoiesis. Proc Natl Acad Sci USA 1996; RNA by HL-60 cells. Blood 1993; 82: 3592–3599. 93: 7900–7904. 22 Kizaki M, Nakajima H, Mori S et al. Novel retinoic acid, 9-cis 4 Fenaux P, Le Dely MC, Castaigne S et al. Effect of all-trans retinoic retinoic acid, in combination with all-trans retinoic acid is an acid in newly diagnosed acute promyelocytic leukemia: results of effective inducer of differentiation of retinoic acid-resistant HL-60 a multicenter randomized trial. Blood 1993; 82: 3241–3249. cells. Blood 1994; 83: 3289–3297. 5 Frankel SR, Eardley A, Miller WH Jr et al. Treatment of acute pro- 23 Miller WH Jr, Jakubowski A, Tong WP et al.9-cis retinoic acid myelocytic leukemia with all-trans retinoic acid: results of the induces complete remission but does not reverse clinically New York study. Ann Intern Med 1994; 120: 278–286. acquired retinoid resistance in acute promyelocytic leukemia. 6 Tallman MS, Andersen JW, Schiffer CA et al. All-trans retinoic acid Blood 1995; 85: 3021–3027. in acute promyelocytic leukemia. New Engl J Med 1997; 337: 24 Miller VA, Rigas JR, Benedetti FM et al. Initial clinical trial of the 1021–1028. pan agonist 9-cis retinoic acid. Clin Cancer Res 7 Fenaux P, Chastang C, Sanz M et al. ATRA followed by chemo- 1996; 2: 471–475. therapy (CT) vs ATRA plus CT and the role of maintenance therapy 25 Jurcic JG, Caron PC, DeBlasio A et al. Targeted therapy with in newly diagnosed acute promyelocytic leukemia (APL): first humanized anti-CD33 monoclonal antibody (HuM195) reduces interim results of APL 93 trial. Blood 1997; 90 (Suppl.): 122a. residual disease in acute promyelocytic leukemia. Blood 1995; 8 Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic 86: 517a. acid + idarubicin) in newly diagnosed acute promyelocytic leuke- 26 Warrell RP Jr, de The´ H, Wang ZY, Degos L. Acute promyelocytic mia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto leukemia. New Engl J Med 1993; 329: 177–189. (GIMEMA) pilot study. Blood 1996; 88: 1390–1398. 27 Muindi JF, Scher HI, Rigas JR et al. Elevated plasma lipid peroxide 9 Soignet S, Fleischauer A, Polyak T et al. All-trans retinoic acid content correlates with rapid plasma clearance of all-trans retinoic significantly increases 5-year survival in patients with acute pro- acid in patients with advanced cancer. Cancer Res 1994; 54: myelocytic leukemia: long-term follow-up of the New York Study. 2125–2128. Cancer Chemotherapy and Pharmacology 1997; 40 (Suppl.): 28 Cornic M, Delva L, Guidez F et al. Induction of retinoic acid- S25–S29. binding protein in normal and malignant human myeloid cells by 10 Muindi JRF, Frankel SR, Huselton C et al. Clinical pharmacology retinoic acid in acute promyelocytic leukemia. Cancer Res 1992; of oral all-trans-retinoic acid in patients with acute promyelocytic 52: 3329–3334. leukemia. Cancer Res 1992; 52: 2138–2142. 29 Kurie JM, Lee JS, Griffin T et al. Phase I trial of 9-cis-retinoic acid 11 Muindi JRF, Frankel S, Miller WH Jr et al. Continuous treatment in adults with solid tumors. Clin Cancer Res 1996; 2: 287–293. with all-trans retinoic acid causes a progressive reduction in 30 Rizvi NA, Marshall JL, Ness E et al. Phase 1 study of 9-cis retinoic plasma drug concentrations: implications for relapse and retinoic acid (ALRT1057 capsules) in adults with advanced cancer. Clin ‘resistance’ in patients with acute promyelocytic leukemia. Blood Cancer Res 1998; 4: 1437–1442. 1992; 79: 299–303. 31 Lee JS, Newman RA, Lippman SM et al. Phase I evaluation of all- 12 Rigas JR, Francis PA, Muindi JRF et al. Constitutive variability in trans retinoic acid in adults with solid tumors. J Clin Oncol 1993; the pharmacokinetics of the natural retinoid, all-trans retinoic 11: 959–966.